Moneycontrol PRO
HomeNewsTrendsHealthCOVID-19 vaccine for 12-14-year-olds to start from March 16; all above 60 years can take boosters

COVID-19 vaccine for 12-14-year-olds to start from March 16; all above 60 years can take boosters

The new decision will mean that, while Corbevax will be offered to the younger adolescents, those in the 15-17-year age group will continue to get Covaxin.

March 14, 2022 / 14:46 IST
Representative image: Reuters

More than two months after opening COVID-19 vaccination for the 15-17-year age group in the country, the Centre has now announced plans to expand the programme further to include the 12-14-year age group, beginning March 16. The estimated population of this age group in India is 7.11 crore, said government sources.

The younger adolescents will be offered Corbevax by Hyderabad based Biological E, a receptor binding domain protein sub unit vaccine, developed in collaboration with the USA’s Baylor College.

This vaccine, to be administered in two doses given 28 days apart, was granted the emergency use authorization by the Drug Controller General of India for use in 12-plus population groups in December last year.

The health ministry said that the decision has been taken following “due deliberations with scientific bodies”.

This means that those born in 2008-2010 will now also be eligible for shots against COVID-19.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Also read: India’s COVID-19 vaccination coverage formidable, but slow boosting policy has many worried

Importantly, the government has also decided that the condition of co-morbidity for COVID-19 precaution dose for population over 60 years of age will now be removed from March 16.

In other words, the entire population above 60 years of age will be eligible for COVID-19 booster doses.

As of now, a little over 9 crore shots against coronavirus have been administered in the 15-17-year age group while more than 2 crore jabs have been given as booster doses to eligible beneficiaries.

Only Covaxin, the COVID-19 vaccine by Bharat Biotech, is permitted for the 15-17-year age group, whose population is estimated at 7.4 crore.

Beginning January 10, 2022, healthcare and frontline workers apart from those above 60 years with underlying diseases were eligible for precaution doses, provided that they had completed 9 months since their second dose.

Sumi Sukanya Dutta
Sumi Sukanya Dutta
first published: Mar 14, 2022 01:55 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347